Vivesto AB (OSTO:VIVE) Current Accrued Expense: kr5.78 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:VIVE Vivesto AB OSTO:VIVE
24 GF Score
Price kr9.02
! 2 Warning Signs
View Full Analysis

What is Vivesto AB Current Accrued Expense?

Vivesto AB OSTO:VIVE -2.04% 24 Current Accrued Expense is kr5.78 Mil as of Jun. 2026. GuruFocus rates OSTO:VIVE with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Vivesto AB's Current Accrued Expense for the quarter that ended in Jun. 2026 was kr5.78 Mil.

Vivesto AB's quarterly Current Accrued Expense increased from Dec. 2025 (kr2.72 Mil) to Mar. 2026 (kr7.22 Mil) but then declined from Mar. 2026 (kr7.22 Mil) to Jun. 2026 (kr5.78 Mil).

Vivesto AB's annual Current Accrued Expense declined from Dec. 2023 (kr13.25 Mil) to Dec. 2024 (kr6.27 Mil) and declined from Dec. 2024 (kr6.27 Mil) to Dec. 2025 (kr2.72 Mil).

Vivesto AB Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Vivesto AB's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivesto AB Current Accrued Expense Chart

Vivesto AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.15 9.31 13.25 6.27 2.72

Vivesto AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.31 7.22 2.72 7.22 5.78
OSTO:VIVE
24GF Score
Vivesto AB OSTO:VIVE
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivesto AB Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of kr5.78 Mil mean?
Vivesto AB (OSTO:VIVE) has a Current Accrued Expense of kr5.78 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Vivesto AB and its competitors.
Is Vivesto AB's Current Accrued Expense too high?
Vivesto AB's current Current Accrued Expense is kr5.78 Mil. Overall, Vivesto AB has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Current Accrued Expense compare to ZTS?
Vivesto AB's Current Accrued Expense of kr5.78 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Vivesto AB and its competitors. Vivesto AB's current Current Accrued Expense is kr5.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OSTO:VIVE) has a current Current Accrued Expense of kr5.78 Mil. The current Current Accrued Expense is kr5.78 Mil. Vivesto AB's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Vivesto AB (OSTO:VIVE), the current Current Accrued Expense is kr5.78 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Other Exchanges OMA:Germany
Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
24GF Score

Get the complete analysis for OSTO:VIVE

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.02
Price